PAI Partners, Grovecourt Capital and HealthEdge are among the PE firms investing in surgical equipment manufacturers and ...

After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a ...

The company's net profit was at Rs 1,182 crore, with revenue at Rs 5,633 crore and EBITDA margin rising to 26.7 percent, in ...

Newspaper publication of notice of loss of share certificates of the company published in the Financial Express English and Gujarati editions, both on May 16, 2025.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Read also: Zydus Lifesciences inks pact with PAI Partners, other shareholders to buy majority stake in Amplitude Surgical SA Punit Patel, President & CEO Zydus Pharmaceuticals USA Inc., speaking on ...

Zydus Lifesciences on Friday said it has received approval from the US health regulator to market a generic medication to treat multiple sclerosis. The company has received approval from the US Food ...

Zydus Lifesciences said that it has has received final approval from the United States Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose ...

Zydus Lifesciences receives USFDA approval to market a generic medication for multiple sclerosis, a generic version of Copaxone. The drug will be manufactured in Europe. New Delhi, May 9 (PTI) Zydus ...